Literature DB >> 20972689

[Repeated percutaneous chemical sympathectomy as a therapeutic option for treating PAD II].

P Gaus1, M Grabener, W Höche, P Saur.   

Abstract

The value of percutaneous chemical lumbar sympathectomy (LSE) for the treatment of peripheral arterial disease (PAD) is still being discussed controversially. In particular, a benefit for Fontaine stage II PAD could not yet be shown. This case report is about a patient suffering from Fontaine stage II PAD. By applying five LSE in regular intervals good symptom control could be achieved and maintained for more than 5 years. The case is an occasion to call for larger controlled studies designed to find out the efficacy of LSE for the treatment of stage II PAD. Mechanisms and available data are discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20972689     DOI: 10.1007/s00482-010-0986-z

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  11 in total

1.  Is sympathectomy of benefit in critical leg ischaemia not amenable to revascularisation?

Authors:  Aliu Sanni; Arief Hamid; Joel Dunning
Journal:  Interact Cardiovasc Thorac Surg       Date:  2005-07-14

2.  [Complications of CT guided lumbar sympathectomy: our own experiences and literature review].

Authors:  S Ernst; W Heindel; R Fischbach; M Gawenda; H J Langen; S Neubauer; T Krahe
Journal:  Rofo       Date:  1998-01

3.  [Prospective study on the effect of lumbar sympathectomy in stage II of arterial occlusive disease].

Authors:  P Waibel
Journal:  Vasa       Date:  1977       Impact factor: 1.961

4.  Phenol sympathectomy in the treatment of intermittent claudication: a controlled clinical trail.

Authors:  T Fyfe; R O Quin
Journal:  Br J Surg       Date:  1975-01       Impact factor: 6.939

5.  Chemical lumbar sympathectomy for ischemic rest pain. A randomized, prospective controlled clinical trial.

Authors:  F W Cross; L T Cotton
Journal:  Am J Surg       Date:  1985-09       Impact factor: 2.565

6.  [Ambulatory, CT-assisted lumbar sympathicolysis in patients with severe peripheral artery disease: influence on peripheral blood flow and clinical outcome].

Authors:  J Nickel; W Brinckmann; R Andresen
Journal:  Zentralbl Chir       Date:  2008-08       Impact factor: 0.942

7.  [Therapy of chronic ischemic pain in peripheral arterial disease. A survey among physicians].

Authors:  L J Rüger; D Irnich; S Grasmueller; P M Lang
Journal:  Schmerz       Date:  2008-04       Impact factor: 1.107

8.  [CT-guided percutaneous lumbar sympathicolysis in peripheral arterial occlusive diseases].

Authors:  S H Duda; P E Huppert; B Heinzelmann; W Schareck; H Seboldt; C D Claussen
Journal:  Rofo       Date:  1994-02

9.  Lumbar neurolytic sympathetic blockades provide immediate and long-lasting improvement of painless walking distance and muscle metabolism in patients with severe peripheral vascular disease.

Authors:  M Gleim; C Maier; U Melchert
Journal:  J Pain Symptom Manage       Date:  1995-02       Impact factor: 3.612

10.  [Sympathetic nervous system and pain--some open questions].

Authors:  G Wasner; R Baron
Journal:  Schmerz       Date:  1998-08-27       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.